Three researchers at ORNL have been named ORNL Corporate Fellows in recognition of significant career accomplishments and continued leadership in their scientific fields.
Oak Ridge National Laboratory scientists recently demonstrated a low-temperature, safe route to purifying molten chloride salts that minimizes their ability to corrode metals. This method could make the salts useful for storing energy generated from the sun’s heat.
ORNL and the Tennessee Valley Authority, or TVA, are joining forces to advance decarbonization technologies from discovery through deployment through a new memorandum of understanding, or MOU.
A team including researchers from the Department of Energy’s Oak Ridge National Laboratory has developed a digital tool to better monitor a condition known as Barrett’s esophagus, which affects more than 3 million people in the United States.
Researchers at Oak Ridge National Laboratory have identified a statistical relationship between the growth of cities and the spread of paved surfaces like roads and sidewalks. These impervious surfaces impede the flow of water into the ground, affecting the water cycle and, by extension, the climate.
Oak Ridge National Laboratory researchers have discovered a better way to separate actinium-227, a rare isotope essential for an FDA-approved cancer treatment.
In the 1960s, Oak Ridge National Laboratory's four-year Molten Salt Reactor Experiment tested the viability of liquid fuel reactors for commercial power generation. Results from that historic experiment recently became the basis for the first-ever molten salt reactor benchmark.
Scientists from Oak Ridge National Laboratory performed a corrosion test in a neutron radiation field to support the continued development of molten salt reactors.
Experts focused on the future of nuclear technology will gather at Oak Ridge National Laboratory for the fourth annual Molten Salt Reactor Workshop on October 3–4.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.